GlassScriptPhysician profile
Vedashree E Panthulu
NPI 1750510723
$26,317.59
in general payments reported to CMS, 2019-2025
38 companies · $3,670 in 2025
The $3,670 reported for 2025 was more than what 81% of Rheumatology providers received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,597 · 2020: $3,263 · 2021: $3,278 · 2022: $4,100 · 2023: $3,800 · 2024: $4,611 · 2025: $3,670.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $12K · Education: $288.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $11,792.20 |
| Education | $287.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $6,349.93 | 2019-2025 | Krystexxa, Enbrel, Evenity |
| Abbvie INC. | $3,911.87 | 2019-2025 | |
| Janssen Biotech, INC. | $3,448.83 | 2019-2025 | Tremfya, Simponi Aria |
| Ucb, INC. | $2,131.37 | 2019-2025 | Cimzia, Bimzelx |
| Pfizer INC. | $1,663.47 | 2019-2025 | |
| Radius Health, INC. | $996.53 | 2019-2025 | Tymlos |
| Aurinia Pharma U.S., INC. | $971.24 | 2021-2025 | Lupkynis |
| Horizon Therapeutics Plc | $915.25 | 2019-2023 | Krystexxa |
| Astrazeneca Pharmaceuticals LP | $853.62 | 2021-2025 | Saphnelo |
| Novartis Pharmaceuticals Corporation | $725.50 | 2019-2025 | |
| Janssen Scientific Affairs, LLC | $642.66 | 2021-2025 | Tremfya |
| Glaxosmithkline, LLC. | $641.38 | 2019-2025 | Benlysta |
| Genzyme Corporation | $532.11 | 2019-2025 | |
| Lilly USA, LLC | $383.62 | 2019-2025 | Taltz, Zepbound |
| E.R. Squibb & Sons, L.L.C. | $309.83 | 2019-2025 | Orencia |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $227.11 | 2021-2025 | Cyltezo |
| Alexion Pharmaceuticals, INC. | $205.26 | 2021-2025 | Strensiq |
| Mallinckrodt Hospital Products INC. | $196.35 | 2022-2025 | Acthar |
| Celgene Corporation | $191.16 | 2019 | |
| Genentech USA, INC. | $173.64 | 2019-2025 | Actemra, Rituxan |
| Fresenius Kabi USA, LLC | $159.88 | 2024-2025 | Tyenne, Idacio |
| Organon LLC | $140.64 | 2021-2025 | Renflexis, Hadlima |
| Sobi, INC | $98.41 | 2019-2025 | |
| Ultragenyx Pharmaceutical INC. | $61.75 | 2022-2023 | Crysvita |
| Abiomed | $60.42 | 2023 | Impella |
| Fidia Pharma USA INC. | $60.14 | 2019-2025 | Hymhyn |
| Tersera Therapeutics LLC | $50.15 | 2021-2023 | Quzyttir |
| Ani Pharmaceuticals, INC. | $32.91 | 2024 | Purified Cortrophin Gel |
| Pacira Therapeutics, INC. | $29.98 | 2019 | |
| Kyowa Kirin, INC. | $25.51 | 2024 | Crysvita |
| Sandoz INC. | $22.07 | 2024 | Hyrimoz |
| Sanofi-Aventis U.S. LLC | $21.14 | 2021 | |
| Pacira Pharmaceuticals Incorporated | $18.23 | 2023 | Iovera, Zilretta |
| Kiniksa Pharmaceuticals International, Plc | $17.13 | 2024 | Arcalyst |
| Almatica Pharma LLC | $16.70 | 2025 | Teriparatide |
| Merck Sharp & Dohme LLC | $15.95 | 2019 | |
| Antares Pharma, INC. | $15.85 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vedashree Panthulu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.